FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221102009> ?p ?o ?g. }

• W4221102009 endingPage "09" @default.
• W4221102009 startingPage "PD13" @default.
• W4221102009 abstract "Abstract Background: NET is one of option in postmenopausal PBC with ER+ and molecular signature is useful tool to determine with/without CT after surgery. We presented a relationship between molecular signature and response of NET in this study cohort (BCRT; 2018). Here we report the primary analysis of NEOS trial, a Phase III study that evaluated long-term prognosis with/without CT in ER+ PBC who received NET. Methods: Postmenopausal BC pts with ER +/HER2 negative, T1c-2, clinically node negative, under 76 years old were enrolled at primary registration. Pts were treated by letrozole (LET) in weeks 24-28 after primary enrollment. Pts experienced progression disease (PD) during neoadjuvant phase or with more than 4 positive lymph nodes in pathological findings after surgery were excluded at randomization and received any systemic therapy driven by investigators before or after surgery. Pts who met eligibility criteria were randomized 1:1 to LET for 4.5-5 years after CT or LET alone for 4.5-5 years without CT after surgery. Primary endpoint is disease-free survival (DFS) with/without adjuvant CT. Secondary endpoints include distant DFS (DDFS), overall survival (OS), DFS/DDFS/OS according clinical response of NET and QoL. Statistical analysis plan is as follow. The Hazard ratio (HR) will be compared with the threshold HRs obtained in a pre-study questionnaire survey to reach a conclusion about the choice between LET plus chemotherapy or LET alone. Based on these survey results, the HR thresholds used to choose between the two treatments were set at 0.9 and 0.6. After amendment, the selection probability was finally set as 80-85%. About 170 events were required for both arms. Results: Between May 2008 and June 2013, 904 patients were enrolled at primary registration from 100 institutions in Japan and 21 pts were withdrawn before neoadjuvant phase. 42pts were excluded by PD during NET. 172pts were not randomized because of non-eligible for second enrolled criteria after surgery and patient’s preference. 669pts were randomized (1:1) to adjuvant CT + ET (333pts) or ET alone (336pts). Patients’ characteristics (age, tumor size, progesterone receptor(PgR) status, nuclear grade (NG), clinical and pathological response of NET and a number of Ax LN metastasis) were well balance among two arms. Median follow up is 7.8 years. Primary endpoint (DFS) was not able to evaluated for necessity of chemotherapy because DFS events (CT+ET:46, ET alone:61) was lower compared with planned numbers (HR:0.74 (95%CI; 0.51, 1.09), P=0.13). DDFS was also not able to evaluated similar with DFS (HR:0.79 (95%CI; 0.46, 1.35) P=0.39). DFS/DDFS rate at 8Y were 85.6%/93.1% and 82.7%/91.7% in CT+ ET and ET alone, respectively. OS was not difference between two arms (HR 0.46 (95%CI; 0.20, 1.07) P=0.072). Both DDFS and locoregional events were lower in CT+ET than ET alone arm. A number of any secondary cancers was higher than DDFS events among both arms. DFS was statistically significant better in CT+ET arm than ET alone arm among any subgroups who &lt; 60 years (HR:0.30, p=0.003, clinical T2 (HR:0.56, p=0.012) and ki67 &gt;20% cases (HR:0.49, P=0.026) at baseline characteristics. No statistically significant difference of DFS between two arms according to response of NET (HR:0.76, P=0.35 in CR and PR group, HR:0.70, p=0.19 in SD group). PgR status, NG, a number of Ax LN metastasis were also not predictive factors about the difference of DFS between CT+ET and ET alone. Conclusion: The decision to use adjuvant chemotherapy could not be based solely on clinical response of NET. Adjuvant chemotherapy should be selected by any clinical factors and genomic tool regardless of response by NET for ER+ PBC. UMIN000001090 Citation Format: Hiroji Iwata, Tatsuya Toyama, Naruto Taira, Norikazu Masuda, Yutaka Yamamoto, Tomomi Fujisawa, Shoichiro Ohtani, Masahiro Kashiwaba, Takehiko Sakai, Yoshie Hasegawa, Rikiya Nakamura, Hiromitsu Akabane, Yukiko Shibahara, Hironobu Sasano, Takuhiro Yamaguchi. Primary analysis from NEOS trial: A randomized phase III study that assessed the long-term prognosis of estrogen receptor positive (ER+) primary breast cancer (PBC) pts who received neoadjuvant endocrine therapy (NET) with/without adjuvant chemotherapy (CT) [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr PD13-09." @default.
• W4221102009 created "2022-04-03" @default.
• W4221102009 creator A5015575554 @default.
• W4221102009 creator A5019325551 @default.
• W4221102009 creator A5024725726 @default.
• W4221102009 creator A5027634537 @default.
• W4221102009 creator A5028637130 @default.
• W4221102009 creator A5036816356 @default.
• W4221102009 creator A5045984290 @default.
• W4221102009 creator A5051908149 @default.
• W4221102009 creator A5065550886 @default.
• W4221102009 creator A5067189124 @default.
• W4221102009 creator A5071947905 @default.
• W4221102009 creator A5073950448 @default.
• W4221102009 creator A5079050158 @default.
• W4221102009 creator A5084823182 @default.
• W4221102009 creator A5087402935 @default.
• W4221102009 date "2022-02-15" @default.
• W4221102009 modified "2023-10-17" @default.
• W4221102009 title "Abstract PD13-09: Primary analysis from NEOS trial: A randomized phase III study that assessed the long-term prognosis of estrogen receptor positive (ER+) primary breast cancer (PBC) pts who received neoadjuvant endocrine therapy (NET) with/without adjuvant chemotherapy (CT)" @default.
• W4221102009 doi "https://doi.org/10.1158/1538-7445.sabcs21-pd13-09" @default.
• W4221102009 hasPublicationYear "2022" @default.
• W4221102009 type Work @default.
• W4221102009 citedByCount "0" @default.
• W4221102009 crossrefType "journal-article" @default.
• W4221102009 hasAuthorship W4221102009A5015575554 @default.
• W4221102009 hasAuthorship W4221102009A5019325551 @default.
• W4221102009 hasAuthorship W4221102009A5024725726 @default.
• W4221102009 hasAuthorship W4221102009A5027634537 @default.
• W4221102009 hasAuthorship W4221102009A5028637130 @default.
• W4221102009 hasAuthorship W4221102009A5036816356 @default.
• W4221102009 hasAuthorship W4221102009A5045984290 @default.
• W4221102009 hasAuthorship W4221102009A5051908149 @default.
• W4221102009 hasAuthorship W4221102009A5065550886 @default.
• W4221102009 hasAuthorship W4221102009A5067189124 @default.
• W4221102009 hasAuthorship W4221102009A5071947905 @default.
• W4221102009 hasAuthorship W4221102009A5073950448 @default.
• W4221102009 hasAuthorship W4221102009A5079050158 @default.
• W4221102009 hasAuthorship W4221102009A5084823182 @default.
• W4221102009 hasAuthorship W4221102009A5087402935 @default.
• W4221102009 hasConcept C121608353 @default.
• W4221102009 hasConcept C126322002 @default.
• W4221102009 hasConcept C143998085 @default.
• W4221102009 hasConcept C168563851 @default.
• W4221102009 hasConcept C203092338 @default.
• W4221102009 hasConcept C207103383 @default.
• W4221102009 hasConcept C2777176818 @default.
• W4221102009 hasConcept C2778292576 @default.
• W4221102009 hasConcept C2778812593 @default.
• W4221102009 hasConcept C2779013556 @default.
• W4221102009 hasConcept C2780275930 @default.
• W4221102009 hasConcept C2780283643 @default.
• W4221102009 hasConcept C44249647 @default.
• W4221102009 hasConcept C530470458 @default.
• W4221102009 hasConcept C71924100 @default.
• W4221102009 hasConceptScore W4221102009C121608353 @default.
• W4221102009 hasConceptScore W4221102009C126322002 @default.
• W4221102009 hasConceptScore W4221102009C143998085 @default.
• W4221102009 hasConceptScore W4221102009C168563851 @default.
• W4221102009 hasConceptScore W4221102009C203092338 @default.
• W4221102009 hasConceptScore W4221102009C207103383 @default.
• W4221102009 hasConceptScore W4221102009C2777176818 @default.
• W4221102009 hasConceptScore W4221102009C2778292576 @default.
• W4221102009 hasConceptScore W4221102009C2778812593 @default.
• W4221102009 hasConceptScore W4221102009C2779013556 @default.
• W4221102009 hasConceptScore W4221102009C2780275930 @default.
• W4221102009 hasConceptScore W4221102009C2780283643 @default.
• W4221102009 hasConceptScore W4221102009C44249647 @default.
• W4221102009 hasConceptScore W4221102009C530470458 @default.
• W4221102009 hasConceptScore W4221102009C71924100 @default.
• W4221102009 hasIssue "4_Supplement" @default.
• W4221102009 hasLocation W42211020091 @default.
• W4221102009 hasOpenAccess W4221102009 @default.
• W4221102009 hasPrimaryLocation W42211020091 @default.
• W4221102009 hasRelatedWork W1982866065 @default.
• W4221102009 hasRelatedWork W2054266788 @default.
• W4221102009 hasRelatedWork W2090744251 @default.
• W4221102009 hasRelatedWork W2130192578 @default.
• W4221102009 hasRelatedWork W2148901112 @default.
• W4221102009 hasRelatedWork W2153213687 @default.
• W4221102009 hasRelatedWork W2158463475 @default.
• W4221102009 hasRelatedWork W2420634159 @default.
• W4221102009 hasRelatedWork W2468229226 @default.
• W4221102009 hasRelatedWork W3095923092 @default.
• W4221102009 hasVolume "82" @default.
• W4221102009 isParatext "false" @default.
• W4221102009 isRetracted "false" @default.
• W4221102009 workType "article" @default.